14.32
0.15 (1.06%)
| Previous Close | 14.17 |
| Open | 13.61 |
| Volume | 1,021,642 |
| Avg. Volume (3M) | 2,458,748 |
| Market Cap | 1,222,322,176 |
| Price / Sales | 72.26 |
| Price / Book | 3.28 |
| 52 Weeks Range | |
| Earnings Date | 25 Feb 2025 - 3 Mar 2025 |
| Operating Margin (TTM) | -716.62% |
| Diluted EPS (TTM) | -3.64 |
| Total Debt/Equity (MRQ) | 0.23% |
| Current Ratio (MRQ) | 6.99 |
| Operating Cash Flow (TTM) | -258.86 M |
| Levered Free Cash Flow (TTM) | -142.71 M |
| Return on Assets (TTM) | -48.67% |
| Return on Equity (TTM) | -81.88% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Syndax Pharmaceuticals, Inc. | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | 4.5 |
| Technical Moving Averages | -1.0 |
| Technical Oscillators | 2.0 |
| Average | 2.13 |
|
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The company's product candidates are entinostat which has direct effects on both cancer cells and immune regulatory cells, SNDX-6352 and SNDX-6352, an anti-CSF-1R monoclonal antibody, to enhance the body's immune response on tumors that have shown sensitivity to immunotherapy. Business activity of the group is primarily functioned through the region of United States. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 0.81% |
| % Held by Institutions | 106.20% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Kynam Capital Management, Lp | 30 Sep 2024 | 5,842,925 |
| Eversept Partners, Lp | 30 Sep 2024 | 4,105,313 |
| Avidity Partners Management Lp | 30 Sep 2024 | 2,455,000 |
| Assenagon Asset Management S.A. | 31 Dec 2024 | 2,064,456 |
| Orbimed Advisors Llc | 30 Sep 2024 | 1,925,300 |
| Woodline Partners Lp | 30 Sep 2024 | 1,896,032 |
| Stempoint Capital Lp | 30 Sep 2024 | 1,731,191 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 51.00 (HC Wainwright & Co., 256.15%) | Buy |
| Median | 38.00 (165.36%) | |
| Low | 16.00 (Scotiabank, 11.73%) | Hold |
| Average | 36.60 (155.59%) | |
| Total | 4 Buy, 1 Hold | |
| Avg. Price @ Call | 16.33 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Scotiabank | 08 Jan 2025 | 16.00 (11.73%) | Hold | 13.81 |
| HC Wainwright & Co. | 10 Dec 2024 | 51.00 (256.15%) | Buy | 14.94 |
| 18 Nov 2024 | 51.00 (256.15%) | Buy | 16.11 | |
| JP Morgan | 21 Nov 2024 | 38.00 (165.36%) | Buy | 15.60 |
| Citigroup | 19 Nov 2024 | 45.00 (214.25%) | Buy | 15.77 |
| Goldman Sachs | 07 Nov 2024 | 33.00 (130.45%) | Buy | 21.52 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |